Frail | Nano Publications

2019 – NBTXR3 for the treatment of locally advanced HNSCC in frail and/or elderly patients: a phase I/II study

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

2019 – Phase I study of hafnium oxide nanoparticles activated by Intensity Modulated Radiation Therapy (IMRT) as a new therapeutic option for elderly or frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, NO-RIGHTS, Tête & Cou

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care. NBTXR3, hafnium oxide nanoparticles injected intratumorally, may represent an option. Otherwise inert, NBTXR3 augments the radiation therapy (RT) dose within tumor cells when activated by RT, increasing tumor cell death compared to RT alone. […]

Continuer la lecture…

2019 – RSNA – Treatment of locally advanced HNSCC by NBTXR3

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Elderly head and neck squamous cell carcinoma (HSNCC) patients (pts) ineligible for standard of care treatment require new therapeutic approaches. NBTXR3, hafnium oxide nanoparticles, may represent such an option. NBTXR3 is activated by radiotherapy, enhancing its effects, leading to physical destruction of cancer cells. A Phase I/II trial [NCT01946867] is underway to evaluate NBTXR3 in elderly (≥70 years) or frail pts with HNSCC of the oral cavity and oropharynx ineligible for cisplatin or intolerant to cetuximab. […]

Continuer la lecture…

2019 – SIOG – NBTXR3 for the treatment of elderly/frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Continuer la lecture…

2019 – ASCO – Phase I NBTXR3 in elderly/frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care treatment. NBTXR3, a crystalline solution of hafnium oxide nanoparticles may represent such an option. Injected intratumorally, NBTXR3 enters tumor cells and yields an increased cell-localized energy deposit upon exposure to radiotherapy (RT), leading to increased tumor cell death compared to the same dose of RT alone. […]

Continuer la lecture…

2019 – ICHNO – Phase I/II NBTXR3 in HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Hafnium oxide nanoparticles, NBTXR3, were developed to augment tumor-localized high energy deposit once activated by ionizing radiation such as Intensity Modulated Radiation Therapy (IMRT) and thus to increase tumor cell death compared to the same dose of radiation. NBTXR3 is characterized by a single intratumoral (IT) administration and fits into standard radiotherapy schedule with no change in patient’s care pathway, treatment protocol or equipment. […]

Continuer la lecture…

2018 – ECHNO 2018 – NBTXR3 for elderly and frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

NBTXR3 administered as a single intratumoral injection and activated by radiotherapy, is currently evaluated in a phase I clinical trial for head and neck cancer. At the 2018 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale Arizona, preliminary results were presented by prof. C. Le Tourneau. […]

Continuer la lecture…

2018 – Multidisciplinary H&N – NBTXR3 for Head and Neck Cancer

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Continuer la lecture…

2021 – Eur J Cancer – NBTXR3 Phase I in HNSCC

Donnée clinique de NBTXR3, NO-RIGHTS, Publications, Tête & Cou

This phase I study assessed the safety of first-in-class radioenhancer nanoparticles, NBTXR3, in elderly or frail patients with locally advanced head and neck squamous cell carcinoma (HNSCC), ineligible for chemoradiation. This is an observational, retrospective, international, study of adult patients with primary non-metastatic STS of the extremities and trunk wall, any grade, diagnosed between 2008 and 2012, treated with at least neoadjuvant treatment and surgical resection and observed for a minimum of 3 years after diagnosis. […]

Continuer la lecture…